Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial.

作者
Meredith M. Regan,Opeyemi Jegede,Charlene Mantia,Thomas Powles,Lillian Werner,Robert J. Motzer,Nizar M. Tannir,Chung-Han Lee,Yoshihiko Tomita,Martin H. Voss,Elizabeth R. Plimack,Toni K. Choueiri,Brian I. Rini,Hans J. Hammers,Bernard Escudier,Laurence Albiges,S. Huo,Viviana Del Tejo,Brian Stwalley,Michael B. Atkins,David F. McDermott
出处
期刊:Clinical Cancer Research [American Association for Cancer Research]
被引量:3
标识
DOI:10.1158/1078-0432.ccr-21-2283
摘要

Purpose: Patients discontinuing immuno-oncology regimens may experience periods of disease control without need for ongoing anticancer therapy, but toxicity may persist. We describe treatment-free survival (TFS), with and without toxicity. Patients and Methods: Data were analyzed from the randomized phase III CheckMate 214 trial of nivolumab plus ipilimumab (n = 550) versus sunitinib (n = 546) for treatment-naive, advanced renal cell carcinoma (aRCC). TFS was estimated by the 42-month restricted mean times defined by the area between Kaplan–Meier curves for two time-to-event endpoints defined from randomization: time to protocol therapy cessation and time to subsequent systemic therapy initiation or death. TFS was subdivided as TFS with and without toxicity by counting days with ≥1 grade ≥3 treatment-related adverse event (TRAE). Results: At 42 months since randomization, 52% of nivolumab plus ipilimumab and 39% of sunitinib intermediate/poor-risk patients were alive; 18% and 5% surviving treatment-free, respectively. Among favorable-risk patients, 70% and 73% of nivolumab plus ipilimumab and sunitinib patients were alive; 20% and 9% treatment-free. Over the 42-month period, mean TFS was over twice as long after nivolumab plus ipilimumab than sunitinib for intermediate/poor-risk (6.9 vs. 3.1 months) and three times as long for favorable-risk patients (11.0 vs. 3.7 months). Mean TFS with grade ≥3 TRAEs was a small proportion of time for both treatments (0.6 vs. 0.3 months after nivolumab plus ipilimumab vs. sunitinib for intermediate/poor-risk, and 0.9 vs. 0.3 months for favorable-risk patients). Conclusions: Patients initiating first-line nivolumab plus ipilimumab for aRCC spent more survival time treatment-free without toxicity versus those on sunitinib, regardless of risk group.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
韭菜盒子发布了新的文献求助10
刚刚
起风了发布了新的文献求助10
1秒前
3秒前
3秒前
QING发布了新的文献求助10
3秒前
斤斤完成签到,获得积分10
3秒前
tcd完成签到,获得积分10
5秒前
小李老博应助韭菜盒子采纳,获得10
6秒前
朴素剑心完成签到,获得积分10
6秒前
称心寒松发布了新的文献求助10
8秒前
希望天下0贩的0应助姜颖采纳,获得10
8秒前
我是老大应助高大雁兰采纳,获得10
10秒前
10秒前
韭菜盒子完成签到,获得积分20
11秒前
筱XY完成签到,获得积分10
12秒前
小懒猪完成签到,获得积分10
12秒前
14秒前
15秒前
随机昵称发布了新的文献求助10
16秒前
17秒前
Jasper应助first采纳,获得10
17秒前
17秒前
18秒前
allia完成签到 ,获得积分10
18秒前
萨特完成签到,获得积分10
18秒前
19秒前
王青文完成签到,获得积分10
19秒前
小马甲应助筱XY采纳,获得10
19秒前
rabwang发布了新的文献求助30
20秒前
21秒前
土豆淀粉完成签到 ,获得积分10
21秒前
蕃茄可乐发布了新的文献求助10
24秒前
ZYD114514完成签到,获得积分10
24秒前
24秒前
geather发布了新的文献求助10
25秒前
追忆完成签到,获得积分10
25秒前
感动白开水完成签到,获得积分10
25秒前
qqqop完成签到,获得积分10
25秒前
罗哈哈完成签到,获得积分20
25秒前
25秒前
高分求助中
All the Birds of the World 4000
Production Logging: Theoretical and Interpretive Elements 3000
Animal Physiology 2000
Les Mantodea de Guyane Insecta, Polyneoptera 2000
Am Rande der Geschichte : mein Leben in China / Ruth Weiss 1500
CENTRAL BOOKS: A BRIEF HISTORY 1939 TO 1999 by Dave Cope 1000
Machine Learning Methods in Geoscience 1000
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 物理 生物化学 纳米技术 计算机科学 化学工程 内科学 复合材料 物理化学 电极 遗传学 量子力学 基因 冶金 催化作用
热门帖子
关注 科研通微信公众号,转发送积分 3740661
求助须知:如何正确求助?哪些是违规求助? 3283536
关于积分的说明 10035580
捐赠科研通 3000305
什么是DOI,文献DOI怎么找? 1646450
邀请新用户注册赠送积分活动 783627
科研通“疑难数据库(出版商)”最低求助积分说明 750411